LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that its Venezuelan operating affiliate, LataMed AI VE, will be featured in an interview in ES Salud Magazine, a healthcare-focused publication. The feature is expected to be published in the July 2026 edition and will include an editorial profile and interview discussing the Company's healthcare technology initiatives, digital healthcare ecosystem strategy, and efforts to improve healthcare accessibility throughout Latin America.
The Company noted that it has received a formal invitation from the publisher to participate in a broader editorial feature package expected to include coverage through both ES Salud Magazine and Eva's Magazine. According to the invitation, the feature is anticipated to be distributed through multiple print, digital, social media, and online publication channels. This expanded distribution is expected to increase visibility among healthcare professionals, industry participants, and stakeholders.
Management stated that the publication provides an opportunity to discuss LataMed AI's evolving healthcare platform, including its telehealth infrastructure, healthcare coordination technologies, payment accessibility initiatives, insurance integration opportunities, pharmacy-related services, and artificial intelligence-driven healthcare solutions under development. The feature is expected to highlight the Company's broader vision of developing an integrated healthcare ecosystem designed to improve accessibility, coordination, and engagement for patients, providers, and stakeholders across emerging markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the importance of engaging with healthcare-focused audiences. “We appreciate the opportunity to share our vision for technology-enabled healthcare solutions and discuss the initiatives we are currently advancing throughout Latin America,” he said. “We believe healthcare accessibility, coordination, and patient engagement remain important challenges across many markets, and we welcome opportunities to participate in industry discussions regarding the role of technology in addressing those challenges.”
The Company expects the feature to be published during July 2026 and intends to provide updates once publication details are finalized, including information regarding publication dates, online availability, print distribution, and access through the publication's online digital channels. For additional information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
